Trial | n | Survival \({E}_{1}\) (Years) | Cost \({C}_{1}\) (CAD) | \(\boldsymbol\rho\) | ||
---|---|---|---|---|---|---|
SE | \(\boldsymbol\sigma\) | SE | \(\boldsymbol\sigma\) | |||
BR.10 | 172 | 0.2930 | 2.717 | 3,757 | 34,840 | 0.124 |
BR.21 | 731 | 0.0325 | 0.622 | 558 | 10,668 | 0.203 |
LY.12a | 519 | 0.0045 | 0.073 | 1,807 | 29,103 | 0.042 |
CO.17 (all patients) | 567 | 0.0184 | 0.309 | 958 | 16,130 | 0.44 |
CO.17 (KRAS subgroup) | 226 | 0.0296 | 0.316 | 1,598 | 16,987 | 0.43 |